Last edition
News about "BaxHTN phase-III trial "
AstraZeneca's Baxdrostat Achieves Significant Blood Pressure Reduction in Phase-III Study
The BaxHTN phase-III trial showed Baxdrostat, an investigational drug developed by AstraZeneca, significantly lowered systolic blood pressure in patients with hard-to-control hypertension, achieving both statistical and clinical relevance.
BaxHTN Phase-III Trial | 01/09/2025 | By Dineshwori | 174
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members